title: [Use of the urinary trypsin inhibitor ulinastatin for acute Kawasaki disease].
abstract: Intravenous immunoglobulin (IVIG) therapy is widely recognized as standard treatment for Kawasaki disease(KD). However, about 20 % of KD patients are resistant to IVIG and are considered to be a high risk group for coronary artery lesions (CAL). Ulinastatin(UTI) is one of the neutrophil elastase inhibitors used for patients with pancreatitis or circulatory shock, and several studies have shown its efficacy for KD. Recently, we demonstrated that initial UTI treatment combined with IVIG decreased the number of patients requiring addi- tional rescue treatment and the occurrence of CAL. In this study, no severe adverse events occurred. Further research and a prospective trial are needed to prove the clinical efficacy and demonstrate the limits of UTI in patients with KD.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kawamura
authors.forename: Takashi
authors.initials: T
authors.lastname: Kanai
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Takeshita
authors.forename: Shigeaki
authors.initials: S
authors.lastname: Nonoyama
mesh_terms: D000208:Acute Disease; D006023:Glycoproteins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy*; D012307:Risk Factors; D014361:Trypsin Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D006023:Glycoproteins; D014361:Trypsin Inhibitors; C028665:urinastatin